Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Short-term Investments (2016 - 2017)

Palisade Bio has reported Short-term Investments over the past 4 years, most recently at $5.0 million for Q4 2017.

  • Quarterly Short-term Investments changed 0.0% to $5.0 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2017, changed 0.0% year-over-year, with the annual reading at $5.0 million for FY2017, 0.0% changed from the prior year.
  • Short-term Investments was $5.0 million for Q4 2017 at Palisade Bio, roughly flat from $5.0 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $15.0 million in Q1 2015 and troughed at $5.0 million in Q4 2016.
  • The 4-year median for Short-term Investments is $7.5 million (2015), against an average of $9.8 million.
  • The largest YoY upside for Short-term Investments was 0.22% in 2015 against a maximum downside of 66.57% in 2015.
  • A 4-year view of Short-term Investments shows it stood at $15.0 million in 2014, then plummeted by 49.91% to $7.5 million in 2015, then tumbled by 33.49% to $5.0 million in 2016, then changed by 0.0% to $5.0 million in 2017.
  • Per Business Quant, the three most recent readings for PALI's Short-term Investments are $5.0 million (Q4 2017), $5.0 million (Q3 2017), and $5.0 million (Q2 2017).